Main Line Center for Skin Surgery
191 Presidential Blvd, Suite LN24
Bala Cynwyd, PA
Phone: 610-664-1414 
Fax: 610-572-7262


New drugs target advanced melanoma

 

New hope for patients with advanced melanoma came at last with the appearance of the first generation of drugs to target melanomas with specific gene mutations. Vemurafenib (Zelboraf) has been shown to prolong survival in patients with metastatic melanoma and is currently the only FDA approved drug that targets melanomas with BRAF mutations. Two new oral medications (trametinib and dabrafenib) have recently been shown to slow down the progression of advanced melanoma as well and are undergoing further study before FDA approval.

2012 Annual Meeting of the American Society of Clinical Oncology